Highest development stage: Phase 1 (NCT05614895)

Development status: Active (as of 2024)

Gram-negative activity

Propensity to select resistant bacteria Yes, at 10^-7 to 10^-9 mutation frequency

Mechanism of Action/Target pathogen: Active against carbapenem-resistant <i>Acinetobacter baumannii</i>; targets the LptB2FGC complex in the Gram-negative inner membrane blocking lipopolysaccharide transport

Additional information: Synthetic compound from the Tranzyme Pharma compound library (RO7075573) which was further modified to produce this second-generation antibiotic; >5-log reduction in neutropenic mouse thigh <i>Acinetobacter baumannii</i> infection model